Top Markets
Coin of the day
TaiRx, Inc. TaiRx, Inc.

TaiRx, Inc.

6580
Classement en actions #25842
TaiRx, Inc., established in 2011 and headquartered in Taipei City, Taiwan, is a... TaiRx, Inc., established in 2011 and headquartered in Taipei City, Taiwan, is a pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for cancer and other diseases. The company's clinical pipeline includes CVM-1118, an oral anti-cancer drug currently undergoing Phase II clinical trials, and Rexis, an add-on injection therapy for sepsis patients, which is in Phase III trials. In its pre-clinical stage, TaiRx is developing TRX-711 for secondary hyperparathyroidism, TRX-920 as an oral delivery formulation, and TRX-105, a molecule designed to treat and alleviate symptoms of various types of colitis. Beyond its developmental drugs, TaiRx also offers Zelnite, a medication that helps maintain patients' blood selenium levels and supports their immune systems. The company's future endeavors also involve the development of nodal diagnostic devices and innovative antibody-based drugs.
Prix de l'action
$0.40861751
Capitalisation boursière
$45.81M
Changement (1 jour)
-1.15%
Changement (1 an)
-46.41%
Pays
TW
Échange TaiRx, Inc. (6580)

Catégorie

Historique du prix de l'action pour TaiRx, Inc. (6580)
Prix de clôture le plus élevé : $0.42 le 2026-08-01

Prix de clôture le plus bas : $1.41 le 2017-06-01
Historique du prix de l'action de TaiRx, Inc. de 2017 à 2026
Performance annuelle du prix de l'action
Année Performance
2026 (TTM) -13.06%
2025 -14.32%
2024 -0.12%
2023 -32.09%
2022 -18.00%
2021 52.04%
2020 57.15%
2019 -14.81%
2018 -18.47%
2017 0.00%
Prix de l'action pour des entreprises similaires ou concurrentes
Entreprise Prix de l'action Variation 1a% Pays
$539.14 36.71%
US
$1.04K 56.86%
NL
$120.74 -14.98%
AU
$761.87 7.04%
CH
$130.43 385.07%
US